Copy

Click here if you cannot read this message

  Press Release 15 December 2015  
 
 
 

Bone Therapeutics completes recruitment of the first half of patients in ALLOB® Phase IIA spinal fusion trial

ALLOB®’s positive safety profile confirmed at mid-point in trial

Gosselies, Belgium, 15 December 2015 - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces it has successfully completed recruitment of the second cohort of four patients in its ALLOB® Phase IIA spinal fusion trial without any safety concerns. Recruitment for this trial remains on track at the midpoint of the trial, with eight out of a total of 16 patients treated.

Spinal fusion is considered the gold standard for the treatment of a broad spectrum of spine disorders and aims to relieve pain and improve function. Approximately one million spinal fusion surgeries are performed each year in Europe and the US (of which approximately half involve lumbar spinal fusion)1 and the global market is estimated to reach $7 billion by 2017.2 Although spinal fusion surgery is routine, it is associated with failure rates of up to 35%.3 Bone Therapeutics’ cell therapy product ALLOB® has been designed to accelerate the fusion process and reduce the failure rate of current surgeries.
 
The pilot Phase IIA study will enrol 16 patients with symptomatic degenerative lumbar disc disease who require interbody fusion surgery.4 An interbody cage is implanted according to the standard-of-care surgical approach, which will be supplemented with ALLOB® in combination with bioceramic granules. Safety and efficacy of this treatment will be assessed over 12 months, using clinical and radiological evaluation. The trial is currently running in eight centres across Belgium. Today, the procedure has been performed in eight patients without any complications or safety issues.
 
ALLOB® is also being evaluated in the treatment of delayed-union fractures and has already reported strong safety and efficacy results. Recently, the Company initiated a novel Phase IIA study with ALLOB® for the treatment of patients with failed spinal fusions. This is the first minimally invasive revision spinal surgery using a bone cell therapy product.

Enrico Bastianelli, CEO of Bone Therapeutics commented: "We are pleased to report today that the spinal fusion trial is on schedule with half of the patients now treated without any safety concerns. We expect to update the market in the first half of 2016 on the efficacy of ALLOB® in the first cohort patients in this trial after the 12-month follow-up period. The excellent safety and efficacy results reported for ALLOB® so far reinforce our confidence in the success of the product and we look forward to further positive data in 2016".

1 Company estimates based on: Hospital discharge data from the Agency for Healthcare Research and Quality for the US; Statistics by the Bundesamt Wiesbaden (Germany); Medtech European Markets for Spinal Fusion Products, March 2006.
2 Global Data report (2014): Spinal fusion – Global Analysis and Market Forecasts.
3 Aghion et al. (2012) Failed back syndrome. Medicine & Health / Rhode Island 95:391-393.
4 Interbody fusion is a type of spinal fusion surgery that involves removal of the disc between two vertebral bodies. To maintain the normal alignment of the spine, an implant, such as a spacer or cage, will be inserted in the space created by the removal of the disc. Subsequently, a bone graft or bone graft substitute is placed between the neighbouring vertebrae to stimulate the fusion process.

 

 
 
 
 
 

To read this press release in French or Dutch, please follow the link below:
FR - NL

 
 

 
 

For further information, please contact:

Bone Therapeutics SA

Enrico Bastianelli, Chief Executive Officer
Wim Goemaere, Chief Financial Officer
Tel: +32 (0)2 529 59 90
investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries
Consilium Strategic Communications

Amber Fennell, Jessica Hodgson,
Lindsey Neville and Hendrik Thys
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com
 

For French Media and Investor Enquiries
NewCap Investor Relations & Financial Communications

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau
Tel: + 33 (0)1 44 71 94 94
bone@newcap.fr

 

 
 

 
 
Follow us

Click here to unsubscribe
 
 

 
         Fond Européen

Le Fonds européen de développement régional et la Wallonie investissent dans votre avenir.

 
 
 
 

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.
PREOB®, Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIB/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB®, its allogeneic “off-the-shelf” bone cell product, is in Phase II for the treatment of delayed-union fractures and spinal fusion procedures. The Company also runs preclinical research programs and develops novel product candidates.
Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 11 patent families. Further information is available at www.bonetherapeutics.com.


Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

 
Bone Therapeutics S.A. • Rue Auguste Piccard, 37 • 6041 Gosselies • Belgium (Europe) • Phone: +32 (0) 2 529 59 90 • Fax: +32 (0) 2 529 59 93 • www.bonetherapeutics.com